288 related articles for article (PubMed ID: 30220008)
1. On the role of the immunoproteasome in transplant rejection.
Basler M; Li J; Groettrup M
Immunogenetics; 2019 Mar; 71(3):263-271. PubMed ID: 30220008
[TBL] [Abstract][Full Text] [Related]
2. The immunoproteasome: a novel drug target for autoimmune diseases.
Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
[TBL] [Abstract][Full Text] [Related]
3. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
[TBL] [Abstract][Full Text] [Related]
4. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.
Basler M; Lindstrom MM; LaStant JJ; Bradshaw JM; Owens TD; Schmidt C; Maurits E; Tsu C; Overkleeft HS; Kirk CJ; Langrish CL; Groettrup M
EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30279279
[TBL] [Abstract][Full Text] [Related]
5. New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells.
Kimura H; Caturegli P; Takahashi M; Suzuki K
J Immunol Res; 2015; 2015():541984. PubMed ID: 26636107
[TBL] [Abstract][Full Text] [Related]
6. No prolongation of skin allograft survival by immunoproteasome inhibition in mice.
Mundt S; Basler M; Sawitzki B; Groettrup M
Mol Immunol; 2017 Aug; 88():32-37. PubMed ID: 28582644
[TBL] [Abstract][Full Text] [Related]
7. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.
Bhattarai S; Ghannam K; Krause S; Benveniste O; Marg A; de Bruin G; Xin BT; Overkleeft HS; Spuler S; Stenzel W; Feist E
J Autoimmun; 2016 Dec; 75():118-129. PubMed ID: 27522114
[TBL] [Abstract][Full Text] [Related]
8. The immunoproteasome in antigen processing and other immunological functions.
Basler M; Kirk CJ; Groettrup M
Curr Opin Immunol; 2013 Feb; 25(1):74-80. PubMed ID: 23219269
[TBL] [Abstract][Full Text] [Related]
9. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.
Basler M; Maurits E; de Bruin G; Koerner J; Overkleeft HS; Groettrup M
Br J Pharmacol; 2018 Jan; 175(1):38-52. PubMed ID: 29034459
[TBL] [Abstract][Full Text] [Related]
11. The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer.
Tripathi SC; Vedpathak D; Ostrin EJ
Cells; 2021 Dec; 10(12):. PubMed ID: 34944095
[TBL] [Abstract][Full Text] [Related]
12. Immunoproteasome-specific inhibitors and their application.
Basler M; Groettrup M
Methods Mol Biol; 2012; 832():391-401. PubMed ID: 22350900
[TBL] [Abstract][Full Text] [Related]
13. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors.
Li J; Koerner J; Basler M; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2019 Mar; 95(3):611-623. PubMed ID: 30685098
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the immunoproteasome: current status and future directions.
Miller Z; Ao L; Kim KB; Lee W
Curr Pharm Des; 2013; 19(22):4140-51. PubMed ID: 23181576
[TBL] [Abstract][Full Text] [Related]
15. The proteasome activator REGγ counteracts immunoproteasome expression and autoimmunity.
Yao L; Zhou L; Xuan Y; Zhang P; Wang X; Wang T; Meng T; Xue Y; Ma X; Shah AS; Shang S; Ma X; Xie W; Wang H; Fu Q; Xia Y; Moses RE; Wang H; Li L; Xiao J; Zhang B; Li X
J Autoimmun; 2019 Sep; 103():102282. PubMed ID: 31171475
[TBL] [Abstract][Full Text] [Related]
16. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
Basler M; Groettrup M
Genes Immun; 2020 Nov; 21(5):273-287. PubMed ID: 32839530
[TBL] [Abstract][Full Text] [Related]
17. A patent review of immunoproteasome inhibitors.
Ogorevc E; Schiffrer ES; Sosič I; Gobec S
Expert Opin Ther Pat; 2018 Jul; 28(7):517-540. PubMed ID: 29865878
[TBL] [Abstract][Full Text] [Related]
18. The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10.
Schmidtke G; Schregle R; Alvarez G; Huber EM; Groettrup M
Mol Immunol; 2019 Sep; 113():22-30. PubMed ID: 29208314
[TBL] [Abstract][Full Text] [Related]
19. Abnormal IFN-gamma-dependent immunoproteasome modulation by Trypanosoma cruzi-infected macrophages.
Bergeron M; Blanchette J; Rouleau P; Olivier M
Parasite Immunol; 2008 May; 30(5):280-92. PubMed ID: 18312504
[TBL] [Abstract][Full Text] [Related]
20. Immunoproteasome Function in Normal and Malignant Hematopoiesis.
Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E
Cells; 2021 Jun; 10(7):. PubMed ID: 34206607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
